Volume 24, Number 1Prostate CancerReal-World Outcomes for Patients With Metastatic Castration-Resistant Prostate Cancer Within a US Community Urology NetworkEmily N. SmythSam WhippleNicholas LazarouKatie GrantArpit KashyapZhanglin L. CuiNadine HaddadArjun V. BalarNeal D ShoreThe role of novel hormonal agents (NHAs) for advanced prostate cancer (PCa) has expanded over time to include treatment of metastatic and nonmetastatic disease. Additionally, in the last 5 years, select poly(ADP-ribose) polymerase (PARP) inhibitors have been FDA-approved and incorporated into treatment guidelines for homologous recombination repair and BRCA mutant metastatic castration-resistant prostate cancer (mCRPC). To understand the evolving treatment landscape and unmet medical needs in mCRPC, treatment patterns, patient characteristics, and outcomes within a large community urology network were evaluated.medical oncologyprostatic neoplasms, castration-resistantUrology